MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

A

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

A

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

A

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

A

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

A

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

Search

Sana Biotechnology Inc

Cerrado

SectorSalud

1.7 -2.86

Resumen

Variación precio

24h

Actual

Mínimo

1.7

Máximo

1.76

Métricas clave

By Trading Economics

Ingresos

11M

-49M

BPA

-0.23

Empleados

194

EBITDA

12M

-45M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+323.73% upside

Dividendos

By Dow Jones

Próximas Ganancias

6 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-222M

396M

Apertura anterior

4.56

Cierre anterior

1.7

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

Sana Biotechnology Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

29 abr 2025, 23:53 UTC

Acciones populares

Stocks to Watch: Starbucks, Snap, Super Micro Computer, Seagate Technology

29 abr 2025, 23:06 UTC

Ganancias

Prudential PLC 1Q New Business Profit Increases by 12%

29 abr 2025, 23:00 UTC

Ganancias

America Movil's Posts Rise in 1Q Profit, Revenue

30 abr 2025, 00:00 UTC

Principales Noticias

Buffett's 'Woodstock for Capitalists' Draws Admirers From Around the Globe -- WSJ

29 abr 2025, 23:46 UTC

Charlas de Mercado

Nikkei May Rise as Fears About U.S. Tariffs Ebb -- Market Talk

29 abr 2025, 23:43 UTC

Charlas de Mercado

Gold Consolidates; Signs of Easing in U.S. Tariffs' Impact May Weigh -- Market Talk

29 abr 2025, 23:41 UTC

Ganancias

China Minsheng Banking 1Q Net Interest Income CNY24.87B Vs. CNY24.26B>1988.HK

29 abr 2025, 23:41 UTC

Ganancias

China Minsheng Banking 1Q Operating Income CNY36.81B Vs. CNY34.27B>1988.HK

29 abr 2025, 23:41 UTC

Ganancias

China Minsheng Banking 1Q Net CNY12.74B Vs. Net CNY13.45B >1988.HK

29 abr 2025, 23:24 UTC

Ganancias

China Vanke 1Q Rev CNY37.99B Vs. CNY61.59B >000002.SZ

29 abr 2025, 23:24 UTC

Ganancias

China Vanke: Increase in Investment Losses Also Hurt Results >000002.SZ

29 abr 2025, 23:24 UTC

Ganancias

China Vanke 1Q Loss CNY6.25B Vs. Loss CNY361.97M >000002.SZ

29 abr 2025, 23:24 UTC

Ganancias

China Vanke: Singificant Decline in Property Sales Weighed on Results >000002.SZ

29 abr 2025, 23:24 UTC

Ganancias

China Vanke 1Q Loss Widened Significantly >000002.SZ

29 abr 2025, 23:15 UTC

Principales Noticias

UPS to Cut 20,000 Jobs After Amazon Breakup -- 2nd Update

29 abr 2025, 23:14 UTC

Ganancias

China Eastern Airlines 1Q Loss CNY995.0M Vs. Loss CNY803.0M >0670.HK

29 abr 2025, 23:14 UTC

Ganancias

China Eastern Airlines: Increased Competition in the Aviation Market Hurt Results >0670.HK

29 abr 2025, 23:14 UTC

Ganancias

China Eastern Airlines 1Q Rev CNY33.41B Vs. CNY33.19B >0670.HK

29 abr 2025, 23:14 UTC

Ganancias

China Eastern Airlines 1Q Loss Widened >0670.HK

29 abr 2025, 23:11 UTC

Ganancias

China Southern Airlines Swung to Loss in 1Q>1055.HK

29 abr 2025, 23:11 UTC

Ganancias

China Southern Airlines 1Q Rev CNY43.41B Vs. CNY44.60B >1055.HK

29 abr 2025, 23:11 UTC

Ganancias

China Southern Airlines: Shift in Traveler Demographics, Competition From High-Speed Rail Networks Also Hurt Results >1055.HK

29 abr 2025, 23:11 UTC

Ganancias

China Southern Airlines 1Q Loss CNY747.0M Vs. Net CNY756.0M >1055.HK

29 abr 2025, 23:11 UTC

Ganancias

China Southern Airlines: CNY Depreciation, Global Supply Chain Constraints Among Factors Weighing on Results >1055.HK

29 abr 2025, 23:07 UTC

Ganancias

Air China 1Q Rev CNY40.02B Vs. CNY40.07B >0753.HK

29 abr 2025, 23:07 UTC

Ganancias

Air China 1Q Losses Widened>0753.HK

29 abr 2025, 23:07 UTC

Ganancias

Air China 1Q Loss CNY2.04B Vs. Loss CNY1.67B >0753.HK

29 abr 2025, 23:02 UTC

Ganancias

COSCO SHIPPING Energy Transportation: Weaker Earnings In International Oil Tanker Fleet Business Weighed on Results>1138.HK

29 abr 2025, 23:02 UTC

Ganancias

COSCO SHIPPING Energy Transportation 1Q Net CNY707.70M Vs. Net CNY1.24B >1138.HK

29 abr 2025, 23:02 UTC

Ganancias

COSCO SHIPPING Energy Transportation 1Q Rev CNY5.75B Vs. CNY5.84B >1138.HK

Comparación entre iguales

Cambio de precio

Sana Biotechnology Inc Esperado

Precio Objetivo

By TipRanks

323.73% repunte

Estimación a 12 meses

Media 7.5 USD  323.73%

Máximo 11 USD

Mínimo 5 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Sana Biotechnology Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

5 ratings

5

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

1.59 / 1.77Soporte y Resistencia

Corto Plazo

Weak Bullish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

No Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Sana Biotechnology Inc

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.